Eris Lifesciences Q3 PAT up 12% to Rs 90 cr, revenue rises 7%
The company launched four new products in the first nine months of FY22, more on the anvil28-01-2022
28-01-2022
Q3FY22 Quarterly Result Announced for Eris Lifesciences Ltd.
Pharmaceuticals company Eris Lifesciences declares Q3FY22 result: Grew by 16.5% YTD in our core Cardio-Metabolic segment despite unprecedented market headwinds in Q2 and Q3 the cardiometabolic market growth hit all-time lows of 4.9% in Q2 and 3.3% in Q3, despite a 4-year median growth rate of 11.2% per quarter Improvement of 128 bps in consolidated 9M EBIDTA margin and 57 bps in 9M PAT margin due to higher MR productivity Growth in standalone YPM to Rs. 5.1 lakh (9M of FY22) compared to Rs. 4.6 lakh (9M of FY21) Operating Cashflow @ 73% of EBIDTA for 9M FY22; Guwahati operations accounted for 81% of revenue in 9M FY22 Standalone debtor days of 41 at the end of Q3 FY22 Tracking to deliver an EPS growth of 14-15% in FY22, on the back of a 21% EPS growth delivered in FY21 Result PDF28-01-2022
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached investor presentation made by the Company.28-01-2022
Eris Lifesciences Ltd - 540596 - Financial Results For The Quarter And Nine Months Ended 31St December, 2021
The Board of Directors of the Company at their meeting held today i.e. January 28, 2022 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021.28-01-2022
Eris Lifesciences Ltd - 540596 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING
The Board of Directors of the Company at their meeting held today i.e. January 28, 2022 duly approved and took on record the limited reviewed Unaudited Standalone Financial Results and the limited reviewed Unaudited Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2021.28-01-2022
Eris Lifesciences Ltd - 540596 - UPDATE ON EARLIER INTIMATION DATED 29TH JULY, 2021
INTIMATION IN TERMS OF REGULATION 30 READ WITH SCHEDULE III PART A (1)21-01-2022
Eris Lifesciences Ltd - 540596 - Shareholding for the Period Ended December 31, 2021
Eris Lifesciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here21-01-2022
Eris Lifesciences Ltd - 540596 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
INTIMATION OF SCHEDULE OF ANALYST & INVESTOR CALL PURSUANT TO REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (SEBI LODR, 2015)20-01-2022
Eris Lifesciences Ltd - 540596 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DEPOSITORIES AND PARTICIPANTS) REGULATIONS, 2018 FOR THE QUARTER ENDED DECEMBER 202120-01-2022
Eris Lifesciences Ltd - 540596 - Board Meeting Intimation for Board Meeting Intimation To Be Held On 28Th January,2022
Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2022 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended on 31st December, 2021 along with limited review reports to be issued by the Statutory Auditors of the Company.20-01-2022